Multimodal management of muscle-invasive bladder cancer.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Current Problems in Cancer

• Publication date

  2014-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.currproblcancer.2014.06.001PMID 25087173PMCID PMC4190161
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Multi-institutional quality care initiative (QCI) to improve the care of patients with invasive bladder cancer (BlCa).

  2014cited by this paper
• Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity.

  2014cited by this paper
• Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.

  2014cited by this paper
• Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233.

  2014cited by this paper
• Long-term outcomes among patients who achieve complete or near-complete responses after the induction phase of bladder-preserving combined modality therapy for muscle-invasive bladder cancer: A pooled analysis of RTOG 9906 and 0233.

  2014cited by this paper
• Double‐blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma

  2014cited by this paper
• Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States.

  2014cited by this paper
• 18F-fluorodeoxyglucose--positron emission tomography/computed tomography aids staging and predicts mortality in patients with muscle-invasive bladder cancer.

  2014cited by this paper
• Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomes

  2014cited by this paper
• S100A9 and EGFR gene signatures predict disease progression in muscle invasive bladder cancer patients after chemotherapy.

  2014cited by this paper
• Comprehensive molecular characterization of urothelial bladder carcinoma

  2014cited by this paper
• Randomized phase III study of adjuvant versus progression-triggered treatment with gemcitabine (G) after radical cystectomy (RC) for locally advanced bladder cancer (LABC) in patients not suitable for cisplatin-based chemotherapy (CBC) (AUO-trial AB22/00).

  2013cited by this paper
• Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial.

  2013cited by this paper
• Trimodality bladder preservation therapy for muscle-invasive bladder cancer.

  2013cited by this paper
• Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03).

  2013cited by this paper
• Expression of VEGF and its receptors VEGFR1/VEGFR2 is associated with invasiveness of bladder cancer.

  2013cited by this paper
• Impact of surgeon and volume on extended lymphadenectomy at the time of robot‐assisted radical cystectomy: results from the International Robotic Cystectomy Consortium (IRCC)

  2013cited by this paper
• Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer.

  2013cited by this paper
• Cancer statistics, 2013

  2013cited by this paper
• Phase II study of neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) chemotherapy in patients with muscle-invasive urothelial cancer (MI-UC): Pathologic and radiologic response, serum tumor markers, and DNA excision repair pathway biomarkers in relation to disease-

  2013cited by this paper
• Phase II study of everolimus in metastatic urothelial cancer

  2013cited by this paper
• HER2 expression in patients (pts) with surgically resected urothelial cancer at high risk of recurrence screened for the phase II randomized, open-label trial of DN24-02, an autologous cellular immunotherapy targeting HER2.

  2013cited by this paper
• Complications after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium.

  2013cited by this paper
• Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: a retrospective analysis from the University of Southern California.

  2013cited by this paper
• Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers.

  2012cited by this paper
• Venous thromboembolism is a relevant and underestimated adverse event in cancer patients treated in phase I studies

  2012cited by this paper
• Breast Cancer as an Acquired Thrombophilic State

  2012cited by this paper
• Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma.

  2012cited by this paper
• Alterations in the PI3K/Akt signaling pathway and association with outcome in invasive high-grade urothelial cancer (UC).

  2012cited by this paper
• Vascular endothelial growth factor, carbonic anhydrase 9, and angiogenin as urinary biomarkers for bladder cancer detection.

  2012cited by this paper
• Do children with central venous line (CVL) dysfunction have increased risk of symptomatic thromboembolism compared to those without CVL-dysfunction, while on cancer therapy?

  2012cited by this paper
• Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.

  2012cited by this paper
• Risk of Venous Thromboembolism in Patients with Cancer: A Systematic Review and Meta-Analysis

  2012cited by this paper
• Unsuspected pulmonary embolism in patients with cancer.

  2012cited by this paper
• The Therapeutic Management of Bleeding and Thrombotic Disorders Complicating CNS Malignancies

  2012influential reference
• Genome Sequencing Identifies a Basis for Everolimus Sensitivity

  2012cited by this paper
• Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial.

  2012cited by this paper
• Relative efficacy of perioperative gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management of locally advanced urothelial carcinoma of the bladder.

  2012cited by this paper
• Balancing Venous Thromboembolism and Hematoma After Breast Surgery

  2012cited by this paper
• Risk factors and clinical outcome of unsuspected pulmonary embolism in cancer patients: a case‐control study

  2012cited by this paper
• Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience.

  2012cited by this paper
• Neoadjuvant accelerated MVAC (AMVAC) in patients with muscle invasive bladder cancer: Results of a multicenter phase II study.

  2012cited by this paper
• Neoadjuvant gemcitabine and cisplatin chemotherapy for locally advanced urothelial cancer of the bladder

  2012cited by this paper
• Venous thromboembolism in cancer patients – Risk scores and recent randomised controlled trials

  2012cited by this paper
• Alterations in the PI3K/Akt signaling pathway and association with outcome in invasive high-grade urothelial cancer (UC).

  2012cited by this paper
• Incidence of venous thromboembolism in patients undergoing surgical treatment for malignancy by type of neoplasm: An analysis of ACS-NSQIP data from 2005 to 2010.

  2012cited by this paper
• Examining the management of muscle-invasive bladder cancer (MIBC) by medical oncologists (MO).

  2012cited by this paper
• Retrospective analysis of clinical outcomes with neoadjuvant cisplatin-based regimens for muscle-invasive bladder cancer.

  2012cited by this paper
• Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer.

  2012cited by this paper
• Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle‐invasive transitional cell carcinoma of the bladder

  2012cited by this paper
• High epidermal growth factor receptor immunohistochemical expression in urothelial carcinoma of the bladder is not associated with EGFR mutations in exons 19 and 21: a study using formalin-fixed, paraffin-embedded archival tissues.

  2012cited by this paper
• Combination of a Novel Gene Expression Signature with a Clinical Nomogram Improves the Prediction of Survival in High-Risk Bladder Cancer

  2012cited by this paper
• Does partial cystectomy compromise oncologic outcomes for patients with bladder cancer compared to radical cystectomy? A matched case-control analysis.

  2012cited by this paper
• Pulmonary embolism in cancer patients.

  2012cited by this paper
• Practical use of perioperative chemotherapy for muscle-invasive bladder cancer: summary of session at the Society of Urologic Oncology annual meeting.

  2012influential reference
• Selective bladder preservation with curative intent for muscle‐invasive bladder cancer: A contemporary review

  2012cited by this paper
• Phase II trial of neoadjuvant gemcitabine (G) and cisplatin (C) with sunitinib in patients (pts) with muscle-invasive bladder cancer (MIBC).

  2012cited by this paper
• Phase II Study of Single-agent Bevacizumab in Japanese Patients with Recurrent Malignant Glioma†

  2012cited by this paper
• [Thromboembolic venous disease as a first sign of neoplastic disease--a case report].

  2012cited by this paper
• Neoadjuvant chemotherapy with DD-MVAC and bevacizumab in high-risk urothelial cancer: Results from a phase II trial at the M. D. Anderson Cancer Center.

  2012cited by this paper
• Association between smoking and risk of bladder cancer among men and women.

  2011cited by this paper
• Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours.

  2011cited by this paper
• Treatment of Muscle Invasive Bladder Cancer: Evidence From the National Cancer Database, 2003 to 2007

  2011cited by this paper
• Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort

  2011cited by this paper
• A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment.

  2011cited by this paper
• Phase II trial of neoadjuvant cisplatin, gemcitabine, and bevacizumab followed by radical cystectomy (RC) in patients with muscle-invasive transitional cell carcinoma (TCC) of the bladder.

  2011cited by this paper
• Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort.

  2011cited by this paper
• Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer.

  2011cited by this paper
• Neoadjuvant gemcitabine plus cisplatin for muscle-invasive bladder cancer.

  2011cited by this paper
• International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial.

  2011cited by this paper
• Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status.

  2011cited by this paper
• Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity.

  2011cited by this paper
• Perioperative outcomes of laparoscopic radical nephroureterectomy and regional lymphadenectomy in patients with upper urinary tract urothelial carcinoma after neoadjuvant chemotherapy.

  2011cited by this paper
• Treatment of muscle invasive bladder cancer: evidence from the National Cancer Database, 2003 to 2007.

  2011cited by this paper
• Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer.

  2011cited by this paper
• Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer

  2010cited by this paper
• Results of a phase III randomized trial of synchronous chemoradiotherapy (CRT) compared to radiotherapy (RT) alone in muscle-invasive bladder cancer (MIBC) (BC2001 CRUK/01/004).

  2010cited by this paper
• A phase II trial of neoadjuvant erlotinib in patients with muscle‐invasive bladder cancer undergoing radical cystectomy: clinical and pathological results

  2010cited by this paper
• Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: Results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study.

  2010cited by this paper
• Fast track program in patients undergoing radical cystectomy: results in 362 consecutive patients.

  2010cited by this paper
• Early and late perioperative outcomes following radical cystectomy: 90-day readmissions, morbidity and mortality in a contemporary series.

  2010cited by this paper
• Lymphovascular invasion and the presence of more than three tumors are associated with poor outcomes of muscle-invasive bladder cancer after bladder-conserving therapies.

  2010cited by this paper
• Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer.

  2010cited by this paper
• Updated results of bladder-sparing trimodality approach for invasive bladder cancer.

  2010cited by this paper
• Phase II study of sunitinib in patients with metastatic urothelial cancer.

  2010cited by this paper
• Early complications of cystectomy after high dose pelvic radiation.

  2010cited by this paper
• The Effectiveness of Off-Protocol Adjuvant Chemotherapy for Patients with Urothelial Carcinoma of the Urinary Bladder

  2010cited by this paper
• A thorough pelvic lymph node dissection in presence of positive margins associated with better clinical outcomes in radical cystectomy patients.

  2009cited by this paper
• Clinical experience with radiotherapy alone and radiochemotherapy with platin based regimens in organ-sparing treatment of invasive bladder cancer.

  2009cited by this paper
• Editorial comment on: Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: long-term follow-up of a phase 2 nonrandomized comparative trial with radical cystectomy.

  2009cited by this paper
• Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience.

  2009cited by this paper
• Partial cystectomy does not undermine cancer control in appropriately selected patients with urothelial carcinoma of the bladder: a population-based matched analysist.

  2009cited by this paper
• Radical cystectomy for urothelial carcinoma of the bladder: an analysis of perioperative and survival outcome

  2009cited by this paper
• Clinical states model for biomarkers in bladder cancer.

  2009cited by this paper
• Sequential adjuvant chemotherapy after surgical resection of high‐risk urothelial carcinoma

  2009cited by this paper
• Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma.

  2009cited by this paper
• A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219).

  2009cited by this paper
• The present and future burden of urinary bladder cancer in the world

  2009cited by this paper
• Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy.

  2009cited by this paper
• Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients

  2009cited by this paper

• GLRX5 is a prognostic marker in bladder cancer and correlates with activation of cancer-associated fibroblasts in the tumor microenvironment.

  2026cites this paper
• Single-cell and immune-context integration identifies basement-membrane/metastasis signatures that sharpen bladder-cancer diagnosis and prognosis

  2026cites this paper
• Evaluation of Event-Free Survival as a Surrogate Endpoint for Overall Survival in Muscle-Invasive Bladder Cancer Following Neoadjuvant Treatment: A Systematic Review and Meta-Analysis

  2025cites this paper
• Survival outcomes and prognostic factors in muscle-invasive bladder cancer: a retrospective cohort study from a Saudi Arabian tertiary center.

  2025cites this paper
• Clinical Predictors and Prognostic Significance of Pathologic Disease Upstaging at Radical Cystectomy in Patients with Muscle-Invasive Bladder Cancer

  2025cites this paper
• Intravesical gemcitabine vs. intravesical Bacillus‑Calmette-Guérin for non‑muscle invasive bladder cancer: A systematic review and meta‑analysis

  2025influential citation
• The role of multidisciplinary care in managing sarcoma in low- and middle-income countries: a focus on treatment outcomes

  2025cites this paper
• Aggressive high-grade urothelial carcinoma transforming into enteric-type adenocarcinoma: a case report

  2025cites this paper
• Bladder Cancer and Vesical Imaging-Reporting and Data System: An Updated Review.

  2025cites this paper
• Tumor suppressor MiRNAs in bladder tumors: From preclinical research to therapeutic applications

  2025cites this paper
• Advancements in bladder cancer treatment: The synergy of radiation and immunotherapy

  2025cites this paper
• Personalizing perioperative therapy in muscle-invasive bladder cancer: balancing oncologic benefit, toxicity, and the risk of overtreatment

  2025cites this paper
• A phenotypic screen identifies xanthohumol and other flavonoids as killers of bladder cancer

  2025cites this paper
• The duality of GSK-3β in urinary bladder cancer: Tumor suppressor and promoter roles through multiple signaling pathways.

  2025cites this paper
• Predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer via interpretable multimodal deep learning

  2025cites this paper
• Treatment Patterns and Radical Cystectomy Outcomes in Patients Diagnosed With Urothelial Nonmetastatic Muscle‐Invasive Bladder Cancer in the United States

  2025cites this paper
• Treatment Patterns, Healthcare Resource Utilization, and Costs Among Patients Diagnosed With Locally Advanced/Metastatic Urothelial Carcinoma Prior to Receiving Enfortumab Vedotin: A Real‐World Evidence Study

  2025cites this paper
• Treatment Patterns, Disease Recurrence, and Overall Survival in Patients With Muscle-Invasive Bladder Cancer After Radical Cystectomy: A Population-Level Claims-Based Analysis.

  2025cites this paper
• Association between vitamin D and bladder neoplasm; a systematic review and meta-analysis

  2024cites this paper
• Retrospective analysis of partial cystectomy in patients with muscle-invasive urothelial carcinoma: A German single-center experience.

  2024cites this paper
• VI steps to achieve VI-RADS assessment.

  2024cites this paper
• Use of inpatient systemic chemotherapy and/or radiotherapy and related predictive factors, healthcare resource utilization, and direct hospitalization costs for metastatic urothelial cancer: findings from a real-world retrospective observational study derived from the national hospital discharge cla

  2024cites this paper
• A Systematic Review of the Use of Surgical Checklists in Transurethral Resection of Bladder Tumour

  2024cites this paper
• Real-world treatment patterns, survival outcomes, and health care resource utilization for locally advanced or metastatic urothelial carcinoma in Spain

  2024cites this paper
• Clinicohistopathological Correlation and Prognostic Significance of Molecular Biomarkers in Urinary Bladder Neoplasms: A Comprehensive Analysis

  2024cites this paper
• PD-L1 expression and its correlation with tumor biomarkers in Chinese urothelial bladder cancer

  2024cites this paper
• Relapse and Survival in Bladder Cancer Patients Undergoing microRNA-129 and microRNA-145 Assays

  2024cites this paper
• Management of urothelial cancer in patients with chronic kidney disease receiving platinum-based chemotherapy.

  2024cites this paper
• Breast cancer stem cells as novel biomarkers.

  2024cites this paper
• The Evolving Role of PD-(L)1 Inhibition in Optimizing Outcomes for High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC): A Podcast

  2024cites this paper
• Discovery of potential FGFR3 inhibitors via QSAR, pharmacophore modeling, virtual screening and molecular docking studies against bladder cancer

  2023cites this paper
• Gelsolin, an Actin-Binding Protein: Bioinformatic Analysis and Functional Significance in Urothelial Bladder Carcinoma

  2023cites this paper
• A review of Glycogen Synthase Kinase-3 (GSK3) inhibitors for cancers therapies.

  2023cites this paper
• Current and Emerging Strategies to Treat Urothelial Carcinoma

  2023cites this paper
• Assessing pentafecta outcomes post radical cystectomy: A tertiary care center study

  2023cites this paper
• Loss of ORP3 induces aneuploidy and promotes bladder cancer cell invasion through deregulated microtubule and actin dynamics

  2023cites this paper
• Clinical and dosimetric outcomes of image-guided, dose-painted radiotherapy in muscle invasive bladder cancer

  2023cites this paper
• Elucidating the Associated Biological Function and Clinical Significance of RHOJ Expression in Urothelial Carcinoma

  2023cites this paper
• Pesticides and Bladder Cancer: Mechanisms Leading to Anti-Cancer Drug Chemoresistance and New Chemosensitization Strategies

  2023cites this paper
• Role of MRI in Detection and Staging of Urinary Bladder Malignancy using VI-RADS.

  2023cites this paper
• Emerging Roles of Circulating Tumor DNA for Increased Precision and Personalization in Radiation Oncology.

  2023cites this paper
• The accuracy of cystoscopy in predicting muscle invasion in newly diagnosed bladder cancer patients

  2023cites this paper
• Comparison of the Efficacy of Postoperative Gemcitabine versus Pirarubicin Perfusion Chemotherapy for Non-Muscle Invasive Bladder Cancer

  2023cites this paper
• Mechanistic review of sulforaphane as a chemoprotective agent in bladder cancer.

  2023cites this paper
• The usage of Pembrolizumab in Metastatic Urothelial Carcinoma

  2023cites this paper
• Hsa-miR-30a-3p overcomes the acquired protective autophagy of bladder cancer in chemotherapy and suppresses tumor growth and muscle invasion

  2022cites this paper
• Bladder-Sparing Approaches to Treatment of Muscle-Invasive Bladder Cancer

  2022cites this paper
• An Immunosenescence-Related Gene Signature to Evaluate the Prognosis, Immunotherapeutic Response, and Cisplatin Sensitivity of Bladder Cancer

  2022cites this paper
• High P2X6 receptor expression in human bladder cancer predicts good survival prognosis

  2022cites this paper
• New bladder cancer non-invasive surveillance method based on voltammetric electronic tongue measurement of urine

  2022cites this paper
• A Review of Immune Checkpoint Blockade for the General Surgeon.

  2022cites this paper
• Muscle invasive bladder cancer and radical cystectomy: a risk predictive model

  2022influential citation
• The global research of bladder cancer immunotherapy from 2012 to 2021: A bibliometric analysis

  2022cites this paper
• (-)-Epigallocatechin-3-Gallate Prevents IL-1β-Induced uPAR Expression and Invasiveness via the Suppression of NF-κB and AP-1 in Human Bladder Cancer Cells

  2022cites this paper
• Transperitoneal Laparoscopic Cystoprostatectomy for Muscle Invasive Bladder Cancer: Results and Oncologic Outcomes in a Single Center in Douala Cameroon

  2022cites this paper
• Frontiers in Non-metastatic, Muscle-invasive Bladder Cancer

  2022cites this paper
• Efficacy of Bladder Intravesical Chemotherapy with Three Drugs for Preventing Non-Muscle-Invasive Bladder Cancer Recurrence

  2021cites this paper
• Risk Stratification of Patients: Risk Tables and Assessment – NMIBC and MIBC

  2021cites this paper
• A Serum Metabolomic Signature for the Detection and Grading of Bladder Cancer

  2021cites this paper
• CULTURE AND MAINTENANCE OF URINE-DERIVED, 3-DIMENSIONAL CANINE TRANSITIONAL CELL CARCINOMA ORGANOIDS

  2021influential citation
• A Mini Review on Epigenetics MiRNAs and their Influence on Bladder Cancer Development

  2021cites this paper
• Music’s effect on pain relief during outpatient urological procedures: a single center, randomized control trial focusing on gender differences

  2021cites this paper
• Investigation of the Inhibitory Effect of Platycodin D in Human Transitional Cell Carcinoma Cell Line 5637.

  2021cites this paper
• Early postoperative complications and 90-day mortality in patients undergoing radical cystectomy

  2020cites this paper
• VI‐RADS for Bladder Cancer: Current Applications and Future Developments

  2020cites this paper
• The Real-World Lifetime Economic Burden of Urothelial Carcinoma by Stage at Diagnosis.

  2020cites this paper
• Low Plasma 25-Hydoxyvitamin D at Diagnosis Predicts Poor Outcomes in Patients with Bladder Cancer: A Prospective Cohort Study

  2020cites this paper
• Upregulation of lncRNA plasmacytoma variant translocation 1 predicts poor prognosis in patients with muscle-invasive bladder cancer

  2020cites this paper
• Development of robust artificial neural networks for prediction of 5-year survival in bladder cancer.

  2020cites this paper
• Thrombomodulin Expression in Bladder Cancer Tissue and Its Association with Prognosis and Patient Survival

  2020cites this paper
• Quality of surgical care can impact survival in patients with bladder cancer after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium

  2020cites this paper
• RRU_A_249417 157..165

  2020cites this paper
• Evaluation of Autofluorescence and Photodynamic Diagnosis in Assessment of Bladder Lesions.

  2020cites this paper
• Incidence and risk factors of suicide among patients diagnosed with bladder cancer: A systematic review and meta-analysis.

  2020cites this paper
• E2F1 Promotes Progression of Bladder Cancer by Modulating RAD54L Involved in Homologous Recombination Repair

  2020cites this paper
• STAT3 enhances radiation-induced tumor migration, invasion and stem-like properties of bladder cancer

  2020cites this paper
• Elevated levels of proinflammatory and anti-inflammatory cytokines in patients with bladder cancer depending on a tumor stage

  2020cites this paper
• Integrative Metabolomic and Transcriptomic Analysis for the Study of Bladder Cancer

  2019cites this paper
• New Insights in the Pathogenesis of Cisplatin-induced Nephrotoxicity

  2019cites this paper
• NUDT21 inhibits bladder cancer progression through ANXA2 and LIMK2 by alternative polyadenylation

  2019cites this paper
• Hyperforin Induces Apoptosis Through Extrinsic/Intrinsic Pathways and Inhibits NF-ĸB-modulated Survival and Invasion Potential in Bladder Cancer

  2019cites this paper
• Glutamine affects T24 bladder cancer cell proliferation by activating STAT3 through ROS and glutaminolysis

  2019cites this paper
• Prognostic stratification of muscle invasive urothelial carcinomas using limited immunohistochemical panel of Gata3 and cytokeratins 5/6, 14 and 20.

  2019cites this paper
• Treatment of Muscle Invasive Urothelial Bladder Cancer- A Review of the Literature

  2019influential citation
• The role of SOX18 in bladder cancer and its underlying mechanism in mediating cellular functions.

  2019cites this paper
• Role of PKC? in Bladder Cancer Progression

  2019cites this paper
• High Apelin Level Indicates a Poor Prognostic Factor in Muscle-Invasive Bladder Cancer

  2019cites this paper
• Multi-omics Integration Analysis Robustly Predicts High-Grade Patient Survival and Identifies CPT1B Effect on Fatty Acid Metabolism in Bladder Cancer

  2019cites this paper
• HBO1 promotes cell proliferation in bladder cancer via activation of Wnt/β‐catenin signaling

  2018cites this paper
• Hypoxia-induced autophagy promotes gemcitabine resistance in human bladder cancer cells through hypoxia-inducible factor 1α activation.

  2018cites this paper
• Urothelial carcinoma: the evolving landscape of immunotherapy for patients with advanced disease

  2018cites this paper
• Ecto-5′-nucleotidase/CD73 contributes to the radiosensitivity of T24 human bladder cancer cell line

  2018cites this paper
• Biological function and molecular mechanism of piRNA in cancer

  2018cites this paper
• FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin‐Containing Chemotherapy

  2018cites this paper
• Systemic Therapy for Advanced Urothelial Carcinoma: Current Standards and Treatment Considerations.

  2018cites this paper
• Effects of human enhancer of filamentation 1 (HEF1) gene on the proliferation, invasion and metastasis of bladder cancer cells.

  2018cites this paper
• Targeting IL-5Rα with antibody-conjugates reveals a strategy for imaging and therapy for invasive bladder cancer

  2017cites this paper
• Hyaluronic acid/ Hyaluronidase as biomarkers for bladder cancer: a diagnostic meta-analysis.

  2017cites this paper
• Regorafenib Induces Apoptosis and Inhibits Metastatic Potential of Human Bladder Carcinoma Cells.

  2017cites this paper
• Activation of a c-Jun N-terminal kinase-mediated autophagy pathway attenuates the anticancer activity of gemcitabine in human bladder cancer cells

  2017cites this paper